Skip to main content

Table 2 QLQ-C30:Scores of Quality of life of patients with head and neck cancer during antineoplastic treatment (n = 63)

From: Health-related quality of life became worse in short-term during treatment in head and neck cancer patients: a prospective study

Quality of Life domains T0 T1 T2 p-value ∆ T1-T0
n (%)
∆ T2-T1
n (%)
∆ T2-T0
n (%)
Mean (SD) Median (p25-p75) Mean (SD) Median (p25-p75) Mean (SD) Median (p25-p75) ≥ ± 10 score points
n (%)
Global health status 67.46 (20.61) 66.66 (50.00–83.33) 69.31 (21.62) 66.66 (50.00–83.33) 61.12 (21.40) 66.66 (50.00–83.33) 0.622 13 (20.6) 20 (31.7) 18 (21.6)
Physical function 80.39 (19.26) 90 (65–100) 81.19 (18.24) 85 (70–100) 79.12 (18.82) 80 (60–100) 0.909 16 (25.4) 18 (28.6) 22 (34.9)
Role function 79.36 (30.92) 100 (66.66–100) 70.10 (35.05) 83.33 (50–100) 67.98 (32.83) 66.66 (50–100) 0.009 23 (36.5) 21 (33.3) 29 (46.0)
Emotional function 68.12 (29.31) 75 (41.66–91.66) 69.84 (29.19) 75 (50–100) 69.70 (28.60) 75 (50–100) 0.986 19 (30.2) 18 (28.6) 19 (30.2)
Cognitive function 78.04 (29.45) 100 (50–100) 80.42 (27.19) 100 (66.66–100) 83.86 (27.10) 100 (83.33–100) 0.035 12 (19.0) 11 (17.5) 8 (12.7)
Social function 85.44 (24.40) 100 (66.66–100) 80.95 (29.00) 100 (66.66–100) 81.48 (29.65) 100 (66.66–100) 0.619 17 (27.0) 11 (17.5) 17 (27.0)
Fatigue 27.51 (31.03) 11.11 (0.0–44.44) 32.62 (29.65) 22.22 (11.11–55.55) 30.15 (28.46) 22.22 (0.0–44.44) 0.010a 30 (47.6) 28 (44.4) 33 (52.4)
Nausea and vomiting 8.46 (20.71) 0.0 (0.0–0.0) 19.57 (24.04) 16.66 (0.0–33.33) 13.22 (25.07) 0.0 (0.0–16.66) < 0.001b 30 (47.6) 9 (14.3) 15 (23.8)
Pain 32.27 (33.84) 16.66 (0.0–50) 30.68 (28.74) 33 (0.0–50) 27.77 (31.82) 16.66 (0.0–50) 0.799 23 (36.5) 20 (31.7) 22 (34.9)
Dyspnoea 11.11 (26.77) 0.0 (0.0–0.0) 13.22 (29.04) 0.0 (0.0–0.0) 13.22 (27.78) 0.0 (0.0–0.0) 0.821 8 (12.7) 8 (12.7) 9 (14.3)
Insomnia 29.10 (39.02) 0.0 (0.0–66.66) 22.22 (35.92) 0.0 (0.0–33.33) 25.39 (37.25) 0.0 (0.0–66.66) 0.630 10 (15.9) 13 (20.6) 11 (17.5)
Appetite loss 25.92 (36.63) 0.0 (0.0–66.66) 43.91 (44.32) 33.33 (0.0–100) 35.97 (43.29) 0.0 (0.0–100) 0.015 28 (44.4) 12 (19.0) 23 (36.5)
Constipation 24.86 (38.31) 0.0 (0.0–33.33) 39.15 (41.71) 33.33 (0.0–100) 37.03 (41.95) 33.33 (0.0–66.66) 0.023 24 (38.1) 18 (28.6) 21 (33.3)
Diarrhea 1.05 (5.89) 0.0 (0.0–0.0) 6.34 (20.61) 0.0 (0.0–0.0) 6.34 (23.07) 0.0 (0.0–0.0) 0.190 7 (11.1) 5 (7.9) 6 (9.5)
Financial difficulties 34.39 (41.02) 0.0 (0.0–66.66) 34.92 (42.09) 0.0 (0.0–100) 39.68 (43.93) 33.33 (0.0–100) 0.744 14 (22.2) 14 (22.2) 19 (30.2)
  1. P-values followed by letters differed statistically according to the post hoc test at the 5% probability level (Friedman test and Dunn post hoc test ajusted by Bonferroni: a difference between T0 and T2; b difference between T0 and T1. ∆ T1-T0, ∆ T2-T1 and ∆ T2-T0 ≥ 10 or ≤ −10 score points: clinically significant negative difference